A Phase Ib Study of YHI-1702 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase Ib Study of YHI-1702 (duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224791

Enrollment

Registered

2019-07-18

Start date

2019-10-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic lymphocytic leukemia/small lymphocytic lymphoma

Interventions

investigational material(s) Generic name etc : YHI-1702 INN of investigational material : Duvelisib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Diagnosis of active CLL or SLL - Disease that has progressed during or relapsed after at least one previous CLL/SLL therapy - Measurable disease > 1.5 cm - ECOG PS of 0 or 1 - Presence of adequate organ and bone-marrow functions

Exclusion criteria

Exclusion criteria: - History of Richter's transformation or prolymphocytic leukemia - Known central nervous system lymphoma or leukemia - Prior exposure to a PI3K inhibitor - Unstable or severe uncontrolled medical condition - Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
efficacy ORR	—

Secondary

Measure	Time frame
safety efficacy PFS OS	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026